BTIG Assumes ArriVent BioPharma at Buy, Announces Price Target of $42
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Jeet Mukherjee assumes ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $42.
BTIG analyst Jeet Mukherjee assumes ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $42.